Ocular FIP treatment gains clearer footing for veterinarians

CURRENT BRIEF VERSION: Ocular FIP treatment is getting sharper focus as new data and clinical education point veterinarians toward antiviral protocols that can preserve vision, not just survival. In a recent VETgirl podcast on ocular feline infectious peritonitis, Dr. Justine Lee highlighted the latest evidence on antiviral therapy for cats with ocular involvement, a subset of FIP that has historically been especially challenging to manage. The episode also underscored a practical point for clinicians: ocular and neurologic involvement are seen much more often in dry FIP than wet FIP, and in some cats uveitis or other eye changes may be the first or dominant sign of disease. That discussion lands amid a broader shift in FIP care: compounded oral GS-441524 became available in the U.S. in June 2024 under FDA enforcement discretion for patient-specific prescriptions, and newer published studies are helping clinicians refine dose, duration, and expectations for cats with ocular or neurologic disease. (fda.gov)

Why it matters: For veterinary teams, ocular FIP is no longer a fringe, largely untreatable presentation. Recent evidence suggests ocular signs can resolve with antiviral treatment, though these cases often require higher-intensity protocols than uncomplicated effusive disease because the eyes and CNS are harder tissues to penetrate. In one 2025 observational case series focused on cats with ocular involvement, remdesivir alone or combined with GS-441524 was associated with improvement in lesions such as panuveitis, posterior uveitis, retinal hemorrhage, keratic precipitates, hyphema, and rubeosis iridis over time, while broader FIP studies have reported that neurologic and ocular signs often resolve within days to weeks when antivirals are used appropriately. The practical takeaway is that early recognition of uveitis, iris color change, dyscoria or anisocoria, retinal lesions, hemorrhage, or hyphema in the right clinical context can materially change outcomes for both the cat and the pet parent. (pubmed.ncbi.nlm.nih.gov)

What to watch: Expect more protocol refinement around dose escalation, treatment duration, and how far data from wet FIP studies can be applied to ocular cases. VETgirl’s recent dosing-and-duration coverage also points to growing interest in whether high-dose induction strategies and objective monitoring markers such as serum amyloid A, alpha-1 acid glycoprotein, and albumin:globulin ratio trends can help guide safer treatment stop decisions, especially in harder-to-clear ocular and neurologic disease. (wormsandgermsblog.com)